✦ LIBER ✦

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma : A phase 2 trial in the North Central Cancer Treatment Group

✍ Scribed by Stephen M. Ansell; David J. Inwards; Kendrith M. Rowland Jr.; Patrick J. Flynn; Roscoe F. Morton; Dennis F. Moore Jr.; Scott H. Kaufmann; Irene Ghobrial; Paul J. Kurtin; Matthew Maurer; Christine Allmer; Thomas E. Witzig

Book ID: 102105783
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 148 KB
Volume: 113
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.23580

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term results of the treatment of pa

Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group

✍ David J. Inwards; Paul A. S. Fishkin; David W. Hillman; David W. Brown; Stephen 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

## Abstract ## BACKGROUND. The objective of this study was to test cladribine (2‐CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL). ## METHODS. Patients with MCL were treated on 2 sequential trials. In Trial 95‐80‐53, patients received 2‐CDA as initial ther